Jane Street’s Insight Molecular Diagnostics IMDX Stock Holding History

Jane Street’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$930K	Buy	+157,682	New	+$778K	﹤0.01%	6698
2026 Q1	–	Sell	-42,469	Closed	-$319K	–	12579
2025 Q4	$319K	Buy	+42,469	New	+$240K	﹤0.01%	8702
2023 Q2	–	Sell	-1,240	Closed	-$8.79K	–	9300
2023 Q1	$8.79K	Sell	1,240 -863	-41%	-$6.41K	﹤0.01%	8750
2022 Q4	$13.5K	Buy	2,103 +567	+37%	+$6.25K	﹤0.01%	8693
2022 Q3	$22K	Buy	+1,536	New	+$26.6K	﹤0.01%	9180
2021 Q2	–	Sell	-1,775	Closed	-$184K	–	10213
2021 Q1	$184K	Buy	+1,775	New	+$169K	﹤0.01%	8326
2020 Q4	–	Sell	-920	Closed	-$26K	–	7922
2020 Q3	$26K	Sell	920 -1,648	-64%	-$47.3K	﹤0.01%	7009
2020 Q2	$98K	Buy	+2,568	New	+$133K	﹤0.01%	6713
2019 Q3	–	Sell	-3,567	Closed	-$178K	–	5541
2019 Q2	$178K	Buy	3,567 +2,969	+496%	+$247K	﹤0.01%	4719
2019 Q1	$47K	Buy	+598	New	+$38.6K	﹤0.01%	4837

Other funds holding IMDX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

FOR

Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street's IMDX Position: Q2 2026 in Review

Jane Street opened a new position in Insight Molecular Diagnostics (IMDX) in Q2 2026: 157,682 shares worth $930K. The stake represents ﹤0.01% of the portfolio and ranks #6698 among its holdings. This is a return to the name: Jane Street previously reported a position in IMDX as recently as Q4 2025.

Jane Street first reported a position in IMDX in Q1 2019 and has held it in 10 quarters since. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

Jane Street held 157,682 shares of Insight Molecular Diagnostics worth $930K as of Q2 2026.
Insight Molecular Diagnostics was a new Jane Street position in Q2 2026.
Insight Molecular Diagnostics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #6698 holding.
Jane Street first reported a position in Insight Molecular Diagnostics in Q1 2019 and has held it in 10 quarters since.
40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.